https://www.fiercepharma.com/pharma/novo-nordisk-makes-headway-bid-to-rule-obesity-market-stunning-phase-3-semaglutide-data
https://www.clinicaltrialsarena.com/news/novo-nordisk-semaglutide-weight/
Presently, Novo Nordisk estimates that fewer than 65 million people globally, of the total assumed sample of 650 million persons that are non diabetic and have an estimated 30+ BMI (body mass index) are utilizing any sort of prescription or medical weight loss aid. The market is essentially untapped.
The drawback for Semaglutide is that application is via injection and serves to inhibit the appetite.
The mean weight loss of the sample size of 1961 patients enrolled in the study was 14.9%.
Robert Kushner, a Northwestern Medicine physician of internal medicine and professor of Medicine in the Division of Endocrinology and Medical Education, said: “This is by far the most effective intervention we have seen for weight management when compared to many of the medications that currently exist.
“Semaglutide sets the standard for a new generation of more effective weight loss drugs.”
In 2020, consensus estimates were that Semaglutide might have the potential to grow sales, specific to weight loss only, to as much as $1.7 billion annually, by 2025.
https://www.evaluate.com/vantage/articles/news/snippets/semaglutide-repeats-obesity-trick
I believe this to be a highly conservative estimate.
https://www.msn.com/en-ca/health/weightloss/a-new-anti-obesity-drug-is-being-heralded-as-a-game-changer/ar-BB1dEIWT?li=AAggFp5
Leave a Reply
You must be logged in to post a comment.